EDITAS MEDICINE, INC. (EDIT) Shareholder Equity
- 2026-06-30: Preferred Stock, Value, IssuedUSD $0.00; Common Stock, Value, IssuedUSD $15.00K; Additional Paid in Capital, Common StockUSD $1.78B; Accumulated Other Comprehensive Income (Loss), Net of TaxUSD $-6.00K.
- 2026-03-31: Preferred Stock, Value, IssuedUSD $0.00; Common Stock, Value, IssuedUSD $10.00K; Additional Paid in Capital, Common StockUSD $1.66B; Accumulated Other Comprehensive Income (Loss), Net of TaxUSD $0.00.
- 2025-12-31: Preferred Stock, Value, IssuedUSD $0.00; Common Stock, Value, IssuedUSD $10.00K; Additional Paid in Capital, Common StockUSD $1.66B; Accumulated Other Comprehensive Income (Loss), Net of TaxUSD $0.00.
- 2025-09-30: Preferred Stock, Value, IssuedUSD $0.00; Common Stock, Value, IssuedUSD $9.00K; Additional Paid in Capital, Common StockUSD $1.64B; Accumulated Other Comprehensive Income (Loss), Net of TaxUSD $0.00.
EDITAS MEDICINE, INC. Shareholder Equity
Filed components and totals, with each concept and unit kept separate. Components can overlap; they are not added together. Missing disclosures remain (m). Original concept pages retain their detailed breakdowns and history.
| Period end | Preferred Stock, Value, Issued USD | Common Stock, Value, Issued USD | Additional Paid in Capital, Common Stock USD | Accumulated Other Comprehensive Income (Loss), Net of Tax USD | Retained Earnings (Accumulated Deficit) USD | Stockholders' Equity Attributable to Parent USD | APIC, Share-based Payment Arrangement, Increase for Cost Recognition USD | Adjustments to Additional Paid in Capital, Increase in Carrying Amount of Redeemable Preferred Stock USD |
|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $0.00 | $15.00K | $1.78B | $-6.00K | $-1.67B | $105.28M | 3 month · $2.19M | (m) |
| 2026-03-31 | $0.00 | $10.00K | $1.66B | $0.00 | $-1.65B | $4.41M | 3 month · $2.10M | (m) |
| 2025-12-31 | $0.00 | $10.00K | $1.66B | $0.00 | $-1.63B | $27.29M | 12 month · $10.00M | (m) |
| 2025-09-30 | $0.00 | $9.00K | $1.64B | $0.00 | $-1.62B | $13.45M | 3 month · $2.23M | (m) |
| 2025-06-30 | $0.00 | $9.00K | $1.62B | $15.00K | $-1.60B | $19.19M | 3 month · $2.66M | (m) |
| 2025-03-31 | $0.00 | $8.00K | $1.61B | $88.00K | $-1.54B | $62.42M | 3 month · $2.98M | (m) |
| 2024-12-31 | $0.00 | $8.00K | $1.60B | $268.00K | $-1.47B | $134.27M | 12 month · $21.42M | (m) |
| 2024-09-30 | $0.00 | $8.00K | $1.60B | $522.00K | $-1.42B | $175.63M | 3 month · $4.80M | (m) |
| 2024-06-30 | $0.00 | $8.00K | $1.59B | $-442.00K | $-1.36B | $232.01M | 3 month · $5.01M | (m) |
| 2024-03-31 | $0.00 | $8.00K | $1.59B | $-326.00K | $-1.29B | $294.40M | 3 month · $7.58M | (m) |
| 2023-12-31 | $0.00 | $8.00K | $1.58B | $198.00K | $-1.23B | $349.10M | 12 month · $19.80M | (m) |
| 2023-09-30 | $0.00 | $8.00K | $1.57B | $-1.45M | $-1.21B | $360.46M | 3 month · $4.73M | (m) |
| 2023-06-30 | (m) | $8.00K | $1.57B | $-2.29M | $-1.17B | $399.92M | 3 month · $5.21M | (m) |
| 2023-03-31 | (m) | $7.00K | $1.45B | $-2.28M | $-1.13B | $317.47M | 3 month · $4.51M | (m) |
| 2022-12-31 | $0.00 | $7.00K | $1.44B | $-3.60M | $-1.08B | $360.68M | 12 month · $29.29M | (m) |
| 2022-09-30 | (m) | $7.00K | $1.44B | $-4.29M | $-1.02B | $414.75M | 3 month · $5.88M | (m) |
| 2022-06-30 | (m) | $7.00K | $1.43B | $-3.39M | $-961.67M | $465.41M | 3 month · $6.62M | (m) |
| 2022-03-31 | (m) | $7.00K | $1.42B | $-2.51M | $-908.21M | $512.76M | 3 month · $11.43M | (m) |
| 2021-12-31 | (m) | $7.00K | $1.41B | $-493.00K | $-857.70M | $553.64M | 12 month · $43.40M | (m) |
| 2021-09-30 | (m) | $7.00K | $1.40B | $-64.00K | $-816.26M | $586.79M | 3 month · $10.01M | (m) |
| 2021-06-30 | (m) | $7.00K | $1.39B | $-71.00K | $-777.18M | $613.36M | 3 month · $13.53M | (m) |
| 2021-03-31 | (m) | $7.00K | $1.36B | $-73.00K | $-721.92M | $638.00M | 3 month · $12.20M | (m) |
| 2020-12-31 | (m) | $6.00K | $1.06B | $-46.00K | $-665.20M | $393.59M | 12 month · $23.16M | (m) |
| 2020-09-30 | (m) | $6.00K | $1.04B | $-48.00K | $-602.70M | $441.15M | 3 month · $5.84M | (m) |
| 2020-06-30 | (m) | $6.00K | $1.04B | $183.00K | $-610.52M | $426.77M | 3 month · $5.42M | (m) |
| 2020-03-31 | (m) | $5.00K | $820.81M | $694.00K | $-586.95M | $234.57M | 3 month · $6.22M | (m) |
| 2019-12-31 | (m) | $5.00K | $811.55M | $107.00K | $-549.22M | $262.44M | 12 month · $27.24M | (m) |
| 2019-09-30 | (m) | $5.00K | $721.40M | $39.00K | $-511.45M | $209.99M | 3 month · $6.56M | (m) |
| 2019-06-30 | (m) | $5.00K | $671.52M | $45.00K | $-478.51M | $193.06M | 3 month · $6.08M | (m) |
| 2019-03-31 | (m) | $5.00K | $661.85M | $29.00K | $-444.72M | $217.16M | 3 month · $7.86M | (m) |
| 2018-12-31 | (m) | $5.00K | $652.46M | $-29.00K | $-416.28M | $236.16M | 12 month · $26.60M | (m) |
| 2018-09-30 | (m) | $5.00K | $615.75M | $-82.00K | $-391.22M | $224.45M | 3 month · $6.70M | (m) |
| 2018-06-30 | (m) | $5.00K | $607.31M | $1.00K | $-375.99M | $231.33M | 3 month · $7.03M | (m) |
| 2018-03-31 | (m) | $4.00K | $584.83M | $-52.00K | $-337.26M | $247.51M | 3 month · $6.53M | (m) |
| 2017-12-31 | (m) | $4.00K | $514.00M | $-76.00K | $-305.85M | $208.08M | 12 month · $15.29M | (m) |
| 2017-09-30 | (m) | $4.00K | $447.47M | $-23.00K | $-269.66M | $177.79M | (m) | (m) |
| 2017-06-30 | (m) | $4.00K | $428.13M | $-67.00K | $-243.06M | $185.00M | (m) | (m) |
| 2017-03-31 | (m) | $4.00K | $423.08M | (m) | $-216.62M | $206.46M | (m) | (m) |
| 2016-12-31 | (m) | $4.00K | $320.13M | (m) | $-185.53M | $134.61M | 12 month · $8.57M | 12 month · $47.00K |
| 2016-09-30 | (m) | $4.00K | $316.32M | (m) | $-146.15M | $170.18M | (m) | (m) |
| 2016-06-30 | (m) | $4.00K | $312.46M | (m) | $-125.13M | $187.33M | (m) | (m) |
| 2016-03-31 | (m) | $4.00K | $307.45M | (m) | $-106.09M | $201.36M | (m) | (m) |
| 2015-12-31 | (m) | (m) | $5.23M | (m) | $-88.35M | $-83.11M | 12 month · $1.17M | 12 month · $394.00K |
| 2014-12-31 | (m) | (m) | (m) | (m) | (m) | $-15.29M | 12 month · $7.00K | 12 month · $309.00K |
| 2013-12-31 | (m) | (m) | (m) | (m) | (m) | $-1.76M | (m) | (m) |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Kyverna Therapeutics, Inc. (KYTX) | United States | $0.434B | -3.60 |
| Scribe Therapeutics, Inc. (SCTX) | United States | $0.410B | |
| Eikon Therapeutics, Inc. (EIKN) | United States | $0.446B | |
| Zura Bio Ltd (ZURA) | $0.398B | -6.56 | |
| Surrozen, Inc./DE (SRZN) | United States | $0.395B | |
| AGENUS INC (AGEN) | United States | $0.383B | 1.41 |
| Tectonic Therapeutic, Inc. (TECX) | United States | $0.469B | -7.68 |
| C4 Therapeutics, Inc. (CCCC) | United States | $0.373B | -5.65 |
| FENNEC PHARMACEUTICALS INC. (FENC) | United States | $0.371B | -115.85 |
| REGENXBIO Inc. (RGNX) | United States | $0.477B | -3.30 |